15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 6 firms covering Aclaris Therapeutics Inc, 6 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets span $10.00 to $16.00, a moderate spread. The average target of $12.00 sits 125% above the current $5.33. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 5 to 6 over recent months. On the fundamentals, the Street sees revenue growth near -27% this year and -6% next, consensus EPS building from about $-0.17 next quarter toward $-0.83 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS6 ratings
Moderate Buy
Strong Buy00%
Buy6100%
Hold00%
Sell00%
Strong Sell00%
Based on 6 analysts giving stock ratings to Aclaris Therapeutics Inc.
As of Jul, 6 of 6 firms rate ACRS a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
ACRS EPS & revenue forecast
EPS · NEXT QUARTER
$-0.17
Range $-0.23 – $-0.11 · 8 analysts · +44% YoY
Next period, 8 analysts expect Aclaris Therapeutics Inc to earn $-0.17 a share (range $-0.23 – $-0.11), versus $-0.12 a year earlier. Full-year consensus is $-0.66, growing to $-0.83 the year after.
REVENUE · NEXT QUARTER
$1.3M
Range $0 – $2.4M · 8 analysts · -59% YoY
Revenue is expected to reach $1.3M (range $0 – $2.4M), -59.0% year-over-year. Full-year consensus is $5.7M, rising to $5.4M next year.
Top analysts covering Aclaris Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ACRS.
#1
Jeff Jones
Oppenheimer · Rank #197
Buy
$10.00+87.8% to target
Overall win rate
34%
+ Follow
#2
Raghuram Selvaraju
HC Wainwright & Co. · Rank #249
Buy
$16.00+200.5% to target
Overall win rate
37%
+ Follow
#3
MF
Martin Fan
Wedbush
Buy
$10.00+87.8% to target
Coverage
—
+ Follow
#4
Louise Chen
Scotiabank
Buy
$9.00+69.0% to target
Coverage
—
+ Follow
#5
Biren Amin
Piper Sandler
Buy
$11.00+106.6% to target
Coverage
—
+ Follow
ACRS stock forecast FAQ
What is ACRS's average 12-month price target?+
The 5 analysts with a live target average $12.00 for Aclaris Therapeutics Inc over the next 12 months, ranging from a $16.00 high to a $10.00 low.
Is ACRS stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 6 analyst ratings, 6 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for ACRS?+
The Street-high target is $16.00 (HC Wainwright & Co.), and the Street-low is $10.00 (Wedbush). The average of all 5 active targets is $12.00.
How many Wall Street analysts cover ACRS?+
6 analysts have an active rating on Aclaris Therapeutics Inc, and 5 firms carry a live 12-month price target.
Who is the most accurate analyst covering ACRS?+
Among analysts who currently cover ACRS, Jeff Jones of Oppenheimer has the strongest overall Quantellect track record (Rank #197). Their current call is Buy with a $10.00 target.
What is Aclaris Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.17 per share (range $-0.23 – $-0.11) across 8 analysts. Full-year EPS is projected at $-0.66, rising to $-0.83 the following year.
How much revenue is Aclaris Therapeutics Inc expected to report next quarter?+
Consensus revenue is $1.3M (range $0 – $2.4M). Full-year revenue is projected at $5.7M, growing to $5.4M next year.
Have analysts been upgrading or downgrading ACRS lately?+
As of Jul, 6 of 6 firms rate ACRS a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ACRS calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
